Guide
Amylin and amylin receptor agonists
Built from index records dated 2026-10-09 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
Amylin and amylin receptor agonists is a group of 5 entries in this index, of which this site describes none and holds all 5 back pending review.
Every entry in this group is held back, so this page explains the group and names its members without describing any of their research records.
What this group is
This group holds 5 entries.
No entry in this group carries a receptor or a pathway in its records. The group is held together by the research subject its literature shares, not by a mechanism, and this site does not invent one for it.
What is held back
5 entries in this group are built and then held back, because publishing them without a qualified reviewer would risk being read as medical guidance. They are: Cagrilintide, Pramlintide, Amylin, Petrelintide and Eloralintide. This page says nothing about what their records contain. Why entries are held back.
What is not known
- Whether the members of this group have anything in common beyond what the counts above show. A shared receptor is a shared target, not a shared result.
- What any of these entries does in a body. Nothing on this site has been read in full, and no record here has been appraised by anyone qualified to appraise it.
- Anything at all about the held-back entries named above, beyond the fact that they exist and are being withheld.
Read next
Where this comes from
This page reprints no wording from the underlying index. These are the published records that index cites for the existence of this group, listed so the grouping can be checked rather than taken on trust.
- Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological reviews (2011). pmid:21742788
- Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular pharmacology (1999). pmid:10385705
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154
- Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current pharmaceutical design (2001). pmid:11472273
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) (2025). pmid:41207310